- Home
- VRNS vs RCUS Comparison
VRNS vs RCUS Comparison
Compare VRNS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | RCUS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VRNS | RCUS |
|---|---|---|
| Price | $33.44 | $24.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 10 |
| Target Price | ★ $42.75 | $31.90 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $270,288,000.00 | $247,000,000.00 |
| Revenue This Year | $18.87 | N/A |
| Revenue Next Year | $17.77 | $45.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.35 | N/A |
| 52 Week Low | $19.70 | $7.92 |
| 52 Week High | $63.90 | $28.72 |
Technical Indicators
Market Signals| Indicator | VRNS | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 52.04 |
| Support Level | $31.20 | $23.91 |
| Resistance Level | $34.07 | $24.33 |
| Average True Range (ATR) | 1.58 | 1.45 |
| MACD | -0.25 | 0.04 |
| Stochastic Oscillator | 42.14 | 57.31 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.